S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RVMD · Revolution Medicines, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Revolution Medicines Inc (RVMD)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$194.15
-2.40
(-1.22%)
● At close: October 21 at 4:00:00 PM EDT
$193.00
-1.28
(-0.66%)
After-Hours:
7:25:10 PM EDT
DAY'S RANGE
$194.15
$194.02
$203.06
52-WEEK RANGE
$194.15
$52.48
$224.31
What's happening
- RVMD is down 1.22% today, trading at $194.15. — Live quote
- Volume today (152,288) is well below its 3-month average of 2,253,790. (Finnhub fundamentals)
- Reports earnings on 2026-11-11 (after market close), 21 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-3.06 actual vs. $-2.02 estimated (-51.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 10
Buy 17
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (29 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RVMD
+146.77%
vs S&P 500
+133.99%
1-YEAR RETURN
RVMD
+263.91%
vs S&P 500
+249.35%
6-MONTH RETURN
RVMD
+31.67%
3-MONTH RETURN
RVMD
+7.23%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-3.06
Est. $-2.02
MISS -51.7%
2026-04-26 (Q1 2026)
$-2.29
Est. $-1.88
MISS -22.1%
2026-01-26 (Q4 2025)
$-1.86
Est. $-1.61
MISS -15.4%
2025-10-26 (Q3 2025)
$-1.61
Est. $-1.45
MISS -11.2%
Valuation Measures & Ratios
Enterprise Value4$42.36B
Forward P/E5—
PEG Ratio6-0.22
Price / Sales (TTM1)3641.42
Price / Book715.28
EV4 / Revenue3660.48
EV4 / EBITDA—
Profit Margin-2833.88%
Operating Margin-3145.03%
Return on Equity (ROE8)-54.06%
Return on Assets (ROA9)-39.14%
Avg Volume (3M)2,253,790
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $39.44B | $19.26B | $8.85B | $6.96B | $6.68B |
| P/E | -23.88 | -15.78 | -9.60 | -9.28 | -10.79 |
| Price/Book | 15.13 | 12.84 | 5.54 | 3.73 | 3.21 |
| EV/EBITDA | -25.38 | -14.96 | -8.73 | — | — |
| ROE | -63.35% | -81.35% | -57.78% | -40.25% | -29.78% |
| ROA | -38.19% | -54.14% | -40.97% | -30.90% | -26.17% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short11,925,485
Change from Prior Settlement+23.34%
% of Float—
Days to Cover (Short Ratio)4.65
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +263.9%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -2833.9%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RVMD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $0 |
| Operating income | -$505.1M | -$445.2M | -$315.3M | -$264.7M | -$240.8M | -$175.7M | -$156.6M | -$140.9M |
| Net income | -$644.4M | -$453.8M | -$305.2M | -$247.8M | -$213.4M | -$156.3M | -$133.2M | -$116.0M |
| EPS (diluted) | $-3.06 | $-2.29 | $-1.61 | $-1.31 | $-1.13 | $-0.94 | $-0.81 | $-0.70 |
| EPS (basic) | $-3.06 | $-2.29 | $-1.61 | $-1.31 | $-1.13 | $-0.94 | $-0.81 | $-0.70 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $4.32B | $2.25B | $2.35B | $2.25B | $2.43B | $2.37B | $2.56B | $1.76B |
| Total liabilities | $1.72B | $753.8M | $723.2M | $655.0M | $564.2M | $287.2M | $293.1M | $196.7M |
| Stockholders' equity | $2.61B | $1.50B | $1.63B | $1.60B | $1.87B | $2.08B | $2.27B | $1.57B |
| Total current assets | $4.03B | $1.97B | $2.08B | $1.98B | $2.18B | $2.13B | $2.33B | $1.58B |
| Total current liabilities | $354.1M | $289.6M | $290.4M | $245.6M | $184.5M | $158.6M | $163.9M | $110.9M |
| Cash & equivalents | $815.4M | $440.9M | $383.7M | $217.4M | $402.4M | $333.6M | $543.1M | $201.3M |
| Marketable securities (current) | $3.12B | $1.47B | $1.64B | $1.71B | $1.73B | $1.77B | $1.75B | $1.35B |
| Property, plant & equipment | $34.6M | $31.5M | $33.2M | $32.9M | $33.0M | $27.2M | $24.3M | $24.8M |
| Goodwill | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M |
| Intangible assets | $55.8M | $55.8M | $55.8M | $55.9M | $56.1M | $56.4M | $56.7M | $56.9M |
| Other non-current assets | $14.8M | $14.5M | $14.8M | $14.9M | $31.4M | $13.1M | $1.7M | $10.3M |
| Accounts payable | $88.4M | $80.5M | $64.6M | $74.8M | $56.8M | $47.5M | $54.4M | $24.5M |
| Accrued liabilities | — | $5.0M | $5.0M | $5.0M | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | $5.1M | $3.3M | $7.9M | $8.2M | $462.0K | $651.0K | $583.0K | $1.3M |
| Other non-current liabilities | $1.6M | $6.9M | $1.2M | $2.5M | $7.2M | $4.1M | $670.0K | $1.6M |
| Common stock & paid-in capital | $21.0K | $19.0K | $19.0K | $18.0K | $18.0K | $18.0K | $18.0K | $16.0K |
| Retained earnings | -$3.97B | -$3.32B | -$2.87B | -$2.50B | -$2.20B | -$1.95B | -$1.74B | -$1.54B |
| Accumulated other comprehensive income (loss) | -$6.0M | -$622.0K | $3.2M | $3.1M | $1.3M | $1.7M | $1.3M | $3.8M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$387.3M | -$354.2M | -$274.2M | -$207.3M | -$221.8M | -$194.4M | -$138.3M | -$130.4M |
| Investing cash flow | -$1.66B | $172.6M | $74.9M | $24.8M | $34.3M | -$15.9M | -$392.9M | -$21.5M |
| Financing cash flow | $2.42B | $238.7M | $365.7M | -$1.6M | $256.6M | $874.0K | $873.8M | $77.3M |
| Free cash flow | -$389.6M | -$355.7M | -$276.2M | -$210.7M | -$229.2M | -$197.7M | -$139.5M | -$133.9M |
| Capital expenditures | $2.3M | $1.5M | $1.9M | $3.3M | $7.5M | $3.3M | $1.2M | $3.5M |
| Depreciation & amortization | $2.4M | $2.3M | $2.3M | $1.5M | $2.3M | $1.7M | $1.7M | $1.6M |
| Share-based compensation | $67.0M | $87.3M | $33.7M | $30.8M | $28.8M | $25.1M | $22.4M | $20.8M |
| Deferred income taxes | — | — | $0 | — | — | — | -$738.0K | — |
| Change in accounts receivable | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Change in accounts payable | $5.0M | $16.9M | -$10.5M | $19.5M | $8.8M | -$8.3M | $29.4M | -$2.8M |
| Purchases of investments | $2.04B | $209.7M | $296.5M | $459.0M | $529.3M | $510.0M | $695.2M | $364.9M |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | $0 | — | — | — | $0 | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M |
| Operating income | -$1.18B | -$689.5M | -$487.2M | -$258.3M | -$188.0M |
| Net income | -$1.13B | -$600.1M | -$436.4M | -$248.7M | -$187.1M |
| EPS (diluted) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 |
| EPS (basic) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 |
| Operating margin | — | — | -$4.2K | -$730 | -$640 |
| Net margin | — | — | -$3.8K | -$703 | -$637 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $2.35B | $2.56B | $2.06B | $811.9M | $738.0M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M |
| Stockholders' equity | $1.63B | $2.27B | $1.83B | $685.2M | $602.6M |
| Total current assets | $2.08B | $2.33B | $1.88B | $660.2M | $589.8M |
| Total current liabilities | $290.4M | $163.9M | $143.9M | $62.0M | $60.4M |
| Cash & equivalents | $383.7M | $543.1M | $696.1M | $161.4M | $108.5M |
| Marketable securities (current) | $1.64B | $1.75B | $1.16B | $483.5M | $468.6M |
| Property, plant & equipment | $33.2M | $24.3M | $22.9M | $18.7M | $11.5M |
| Goodwill | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M |
| Intangible assets | $55.8M | $56.7M | $57.7M | $58.8M | $59.9M |
| Other non-current assets | $14.8M | $1.7M | $7.0M | $2.9M | $758.0K |
| Accounts payable | $64.6M | $54.4M | $61.8M | $21.3M | $14.1M |
| Accrued liabilities | $5.0M | — | — | — | — |
| Deferred revenue (current) | — | — | $0 | $4.5M | $12.4M |
| Other current liabilities | $7.9M | $583.0K | $3.9M | $505.0K | $311.0K |
| Other non-current liabilities | $1.2M | $670.0K | $1.5M | $301.0K | $634.0K |
| Common stock & paid-in capital | $19.0K | $18.0K | $16.0K | $9.0K | $8.0K |
| Retained earnings | -$2.87B | -$1.74B | -$1.14B | -$701.3M | -$452.6M |
| Accumulated other comprehensive income (loss) | $3.2M | $1.3M | $544.0K | -$1.8M | -$376.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$897.7M | -$557.4M | -$350.6M | -$224.4M | -$147.2M |
| Investing cash flow | $118.1M | -$554.4M | -$342.6M | -$24.1M | -$142.1M |
| Financing cash flow | $621.5M | $959.4M | $1.23B | $301.4M | $294.2M |
| Free cash flow | -$913.7M | -$567.7M | -$358.3M | -$235.2M | -$153.7M |
| Capital expenditures | $16.0M | $10.3M | $7.7M | $10.8M | $6.5M |
| Depreciation & amortization | $7.8M | $6.6M | $5.0M | $4.0M | — |
| Share-based compensation | $118.4M | $79.2M | $61.8M | $31.2M | $20.7M |
| Deferred income taxes | $0 | -$738.0K | -$3.8M | -$420.0K | — |
| Change in accounts receivable | $0 | -$1.3M | -$3.4M | -$1.3M | -$464.0K |
| Change in accounts payable | $9.5M | -$6.5M | $32.5M | $7.3M | $2.2M |
| Purchases of investments | $1.79B | $2.14B | $1.06B | $612.8M | $671.3M |
| Dividends paid | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $0 | $4.0M | $0 | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RVMD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-18 to 2026-09-29
Recent transactions
- Insiders have net sold 406,290 shares over the last 182 days, across 0 purchases and 92 sales.
- Most recent: Sandler Alan B. (Chief Development Officer) — Option exercise of 6,000 shares on 2026-09-29.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)406,290 sh(92 txns)
Net Shares-406,290
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Sandler Alan B. | Chief Development Officer | Option exercise | 2026-09-29 | 6,000 |
| Cislini Jeff | SVP & General Counsel | Open market sale | 2026-09-25 | 765 |
| Mancini Anthony | See Remarks | Option exercise | 2026-09-25 | 3,121 |
| ANDERSON ELIZABETH M | Reporting person | Option exercise | 2026-09-22 | 5,070 |
| Kelsey Stephen Michael | See Remarks | Open market sale | 2026-09-16 | 85 |
| Horn Margaret A | Chief Operating Officer | Open market sale | 2026-09-16 | 76 |
| GOLDSMITH MARK A | See Remarks | Open market sale | 2026-09-16 | 213 |
| Anders Jack | Chief Financial Officer | Open market sale | 2026-09-16 | 61 |
| Kim Lorence H. | Reporting person | Open market sale | 2026-09-08 | 706 |
| Patel Sushil | Reporting person | Option exercise | 2026-06-29 | 2,955 |
| Borisy Alexis | Reporting person | Grant / award | 2026-06-18 | 1,191 |
| Horning Sandra | Reporting person | Grant / award | 2026-06-18 | 1,191 |
| Clyburn Frank | Reporting person | Grant / award | 2026-06-18 | 1,191 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Sandler Alan B. | Chief Development Officer | Option exercise | 6,000 | $58.84 |
| 2026-09-29 | Sandler Alan B. | Chief Development Officer | Open market sale | 2,200 | $200.82 |
| 2026-09-29 | Sandler Alan B. | Chief Development Officer | Open market sale | 1,609 | $201.72 |
| 2026-09-29 | Sandler Alan B. | Chief Development Officer | Open market sale | 1,000 | $202.81 |
| 2026-09-29 | Sandler Alan B. | Chief Development Officer | Open market sale | 1,199 | $203.91 |
| 2026-09-29 | Sandler Alan B. | Chief Development Officer | Open market sale | 301 | $204.72 |
| 2026-09-25 | Cislini Jeff | SVP & General Counsel | Open market sale | 765 | $207.32 |
| 2026-09-25 | Mancini Anthony | See Remarks | Option exercise | 3,121 | $33.62 |
| 2026-09-25 | Mancini Anthony | See Remarks | Open market sale | 3,121 | $200.54 |
| 2026-09-24 | Mancini Anthony | See Remarks | Open market sale | 587 | $200.00 |
| 2026-09-22 | ANDERSON ELIZABETH M | Reporting person | Option exercise | 5,070 | $1.12 |
| 2026-09-22 | ANDERSON ELIZABETH M | Reporting person | Open market sale | 910 | $191.85 |
| 2026-09-22 | ANDERSON ELIZABETH M | Reporting person | Open market sale | 4,985 | $192.54 |
| 2026-09-22 | ANDERSON ELIZABETH M | Reporting person | Open market sale | 2,648 | $193.44 |
| 2026-09-22 | ANDERSON ELIZABETH M | Reporting person | Open market sale | 1,500 | $194.59 |
| 2026-09-22 | ANDERSON ELIZABETH M | Reporting person | Open market sale | 100 | $195.15 |
| 2026-09-18 | Mancini Anthony | See Remarks | Open market sale | 1,764 | $196.94 |
| 2026-09-16 | Sandler Alan B. | Chief Development Officer | Open market sale | 5 | $194.96 |
| 2026-09-16 | Sandler Alan B. | Chief Development Officer | Open market sale | 336 | $199.30 |
| 2026-09-16 | Mancini Anthony | See Remarks | Open market sale | 27 | $195.05 |
| 2026-09-16 | Mancini Anthony | See Remarks | Open market sale | 1,747 | $199.30 |
| 2026-09-16 | Kelsey Stephen Michael | See Remarks | Open market sale | 85 | $195.01 |
| 2026-09-16 | Kelsey Stephen Michael | See Remarks | Open market sale | 5,484 | $199.30 |
| 2026-09-16 | Horn Margaret A | Chief Operating Officer | Open market sale | 76 | $195.01 |
| 2026-09-16 | Horn Margaret A | Chief Operating Officer | Open market sale | 4,891 | $199.30 |
| 2026-09-16 | GOLDSMITH MARK A | See Remarks | Open market sale | 213 | $195.01 |
| 2026-09-16 | GOLDSMITH MARK A | See Remarks | Open market sale | 13,775 | $199.30 |
| 2026-09-16 | Cislini Jeff | SVP & General Counsel | Open market sale | 52 | $195.01 |
| 2026-09-16 | Cislini Jeff | SVP & General Counsel | Open market sale | 3,314 | $199.30 |
| 2026-09-16 | Anders Jack | Chief Financial Officer | Open market sale | 61 | $195.00 |
| 2026-09-16 | Anders Jack | Chief Financial Officer | Open market sale | 3,992 | $199.30 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Option exercise | 52,500 | $42.45 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Option exercise | 40,031 | $40.74 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Open market sale | 800 | $198.55 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Open market sale | 11,833 | $200.11 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Open market sale | 13,368 | $200.78 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Open market sale | 21,447 | $201.75 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Open market sale | 18,869 | $203.06 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Open market sale | 17,949 | $203.87 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Open market sale | 4,995 | $204.84 |
| 2026-09-11 | Kelsey Stephen Michael | See Remarks | Open market sale | 3,270 | $205.81 |
| 2026-09-10 | Mancini Anthony | See Remarks | Option exercise | 9,363 | $33.62 |
| 2026-09-10 | Mancini Anthony | See Remarks | Open market sale | 6,019 | $203.28 |
| 2026-09-10 | Mancini Anthony | See Remarks | Open market sale | 5,530 | $204.14 |
| 2026-09-10 | Mancini Anthony | See Remarks | Open market sale | 2,420 | $205.05 |
| 2026-09-10 | Mancini Anthony | See Remarks | Open market sale | 1,179 | $206.10 |
| 2026-09-10 | Mancini Anthony | See Remarks | Open market sale | 300 | $207.17 |
| 2026-09-08 | Kim Lorence H. | Reporting person | Open market sale | 706 | $206.60 |
| 2026-09-08 | Kim Lorence H. | Reporting person | Open market sale | 999 | $207.33 |
| 2026-09-08 | Kim Lorence H. | Reporting person | Open market sale | 3,587 | $208.55 |
| 2026-09-08 | Kim Lorence H. | Reporting person | Open market sale | 2,853 | $209.56 |
| 2026-09-08 | Kim Lorence H. | Reporting person | Open market sale | 4,730 | $210.50 |
| 2026-09-08 | Kim Lorence H. | Reporting person | Open market sale | 3,844 | $211.36 |
| 2026-09-08 | Kim Lorence H. | Reporting person | Open market sale | 371 | $212.27 |
| 2026-08-31 | Kim Lorence H. | Reporting person | Open market sale | 300 | $200.56 |
| 2026-08-31 | Kim Lorence H. | Reporting person | Open market sale | 6,597 | $201.47 |
| 2026-08-31 | Kim Lorence H. | Reporting person | Open market sale | 12,919 | $202.48 |
| 2026-08-31 | Kim Lorence H. | Reporting person | Open market sale | 26,160 | $203.55 |
| 2026-08-31 | Kim Lorence H. | Reporting person | Open market sale | 7,271 | $204.35 |
| 2026-08-31 | Kim Lorence H. | Reporting person | Open market sale | 2,128 | $205.19 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:55 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 8-K | 2026-10-08 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-29 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-24 | 4 | 2026-09-22 | View on SEC.gov → |
| 2026-09-22 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
Recent news
Headlines about RVMD (Revolution Medicines, Inc.). Links open the publisher — we don’t host full articles.
-
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Yahoo Finance · 2026-10-21 -
RVMD Reiterated by TD Cowen -- Price Target Announced at $250
GuruFocus · 2026-10-21 -
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Yahoo Finance · 2026-10-21 -
RVMD261218C00320000 Interactive Stock Chart | RVMD Dec 2026 320.000 call Stock
Yahoo! Finance Canada · 2026-10-20 -
RVMD Stock Rallies As RASONQUE Launch And EU Nod Fuel Hype
Timothy Sykes · 2026-10-20 -
Revolution Medicines Inc Stock (RVMD) Moved Up by 7.41% on Oct 20: Facts Behind the Movement
TradingKey · 2026-10-20 -
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
Yahoo · 2026-10-20 -
Revolution Medicines Kicks Off Lung-Cancer Trial as Truist Lifts Rasonque Revenue Forecast - ad-hoc-news.de
ad-hoc-news.de · 2026-10-20
No headlines in this category right now — try “All”.